Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous limbal progenitor cells is an advanced cell therapy and regenerative medicine product being developed by Fundació Clínic per a la Recerca Biomèdica for the treatment of unilateral severe limbal stem cell deficiency (LSCD). The therapeutic process involves harvesting a small biopsy of sclero-corneal limbal tissue from the patient's healthy fellow eye, expanding the limbal progenitor and epithelial stem cells ex vivo on a human amniotic membrane scaffold, and subsequently transplanting the resulting cell sheet onto the diseased ocular surface. This approach aims to restore the limbal stem cell niche, promote corneal epithelial homeostasis, and rebuild corneal integrity to improve vision. The therapy is currently being evaluated in a Phase 2 clinical trial in Spain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous limbal progenitor cells.